Education
About Us
Working with TipRanks
Follow Us
Aethlon (AEMD)
:AEMD
AEMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $1.79
Previous CloseN/A
Volume1.62M
Average Volume (3M)113.29K
Market Cap
$5.76M
Enterprise Value$7.91M
Total Cash (Recent Filing)$67.95K
Total Debt (Recent Filing)$1.92M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Jun 26, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding16,085,768
10 Day Avg. Volume74,854
30 Day Avg. Volume113,287
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.02
Enterprise Value/Ebitda-0.84
Forecast
1Y Price Target
$7.00Price Target Upside1742.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Aethlon Medical News
PremiumCompany Announcements
Aethlon’s Earnings Call: Trials and Cost Strategies
PremiumCompany Announcements
Aethlon Medical Reports Q3 Results and Corporate Update
PremiumCompany Announcements
Aethlon Medical Achieves Milestone in Oncology Trials
PremiumPre-Earnings
Aethlon (AEMD) Q3 Earnings Cheat Sheet---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressSignificant progress was made with Aethlon's oncology program, including the first treatment of a patient with the company's Hemopurifier.
Financial ManagementAEMD has taken measures to improve operating expense management, which is expected to extend its cash runway and support ongoing clinical activities.
Patient EnrollmentTwo hospitals in Australia are open for patient enrollment, and additional sites in Australia and India have received ethics committee approval.
Bears Say
Clinical Trial RiskRisks to our investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, and an untested commercialization strategy.
Commercialization UncertaintyThere is uncertainty regarding the potential approval and commercialization of the Hemopurifier in the oncology and organ transplant markets.
Revenue RecognitionDespite clinical progress and financial discipline, AEMD did not recognize any revenue during the F3Q25 quarter, and no revenue is forecasted for FY25 or FY26.
---
Ownership Overview
1.88% Insiders
0.71% Mutual Funds
7.16% Other Institutional Investors
90.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AEMD FAQ
What was Aethlon’s price range in the past 12 months?
Aethlon lowest stock price was $0.24 and its highest was $1.79 in the past 12 months.
What is Aethlon’s market cap?
Aethlon’s market cap is $5.76M.
When is Aethlon’s upcoming earnings report date?
Aethlon’s upcoming earnings report date is Jun 26, 2025 which is in 63 days.
How were Aethlon’s earnings last quarter?
Aethlon released its earnings results on Feb 12, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.203 by $0.073.
Is Aethlon overvalued?
According to Wall Street analysts Aethlon’s price is currently Undervalued.
Does Aethlon pay dividends?
Aethlon does not currently pay dividends.
What is Aethlon’s EPS estimate?
Aethlon’s EPS estimate is -0.14.
How many shares outstanding does Aethlon have?
Aethlon has 16,085,768 shares outstanding.
What happened to Aethlon’s price movement after its last earnings report?
Aethlon reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.203. Following the earnings report the stock price went down -5.97%.
Which hedge fund is a major shareholder of Aethlon?
Currently, no hedge funds are holding shares in AEMD
---
Company Description
Aethlon
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
---
AEMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call indicated a balanced outlook for Aethlon Medical, with significant strides in protocol amendments and cost reduction efforts. However, challenges in patient enrollment and an anticipated increase in operating expenses present ongoing hurdles.Read More>---
AEMD Stock 12 Month Forecast
Average Price Target
$7.00
▲(1742.11% Upside)
Technical Analysis
Trinity Biotech
―
Purple Biotech
―
Aytu BioScience
―
BioNano Genomics
―
Mainz Biomed B.V.
―
Best Analysts Covering AEMD
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-55.17%
reiterated a buy rating 2 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -55.17% per trade.
---